Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: A pilot study

Drugs under Experimental and Clinical Research

Volumn 31, Issue 4, 2005, Pages 161-168

  Venturini, Ivo ^a   Ferrieri, A ^b   Farina, F ^a   Cosenza, F ^a   Avallone, R ^a   Corsi, L ^a   Baraldi, M ^a   Zeneroli, M L ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Alfa Wassermann SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DIAZEPAM; LACTULOSE; PLACEBO; RADIOLIGAND; RIFAXIMIN;

ADULT; AGED; ARTICLE; BACTERIAL FLORA; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER CIRRHOSIS; MALE; PILOT STUDY; RADIOASSAY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BENZODIAZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION; FEMALE; HUMANS; LACTULOSE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; RIFAMYCINS;

EID: 26244453927     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Zeneroli M.L. Hepatic encephalopathy. Experimental studies in a rat model of fulminant hepatic failure. J. Hepatol., 1, 301, 1985.
2. Jones E.A., Skolnick R, Gammal H., Basile A.S., Mullen K.D. The γ-aminobutyric acid-A (GABA-A) receptor complex and hepatic encephalopathy. Some recent advances. Ann. Intern. Med., 110, 532, 1989.
3. Schafer D.F., Jones E.A. Hepatic encephalopathy and the γ-aminobutyric acidneurotransmittersystem. Lancet, 1(8262), 18, 1982.
4. De Bias A.L., Park D., Friedrich P. Endogenous benzodiazepine-like molecules in human, rat and bovine brains studied with a monoclonal antibody to benzodiazepines. Brain Res., 413, 275, 1987.
5. Medina J.H., Pena C., Levi de Stein M., Wolfman C., Paladini A.C. Benzodiazepine-like molecules as well as other ligands for the brain benzodiazepine receptors, are relatively common constituents of plants. Biochem. Biophys. Res. Comm., 165, 547, 1989.
6. Unseld E., Klotz U. Benzodiazepines: Are they of natural origin? Pharmac. Res., 6, 1, 1989.
7. Zeneroli M.L., Venturini L, Stefanelli S., et al. Antibacterial activity of rifaximin reduces the levels of benzodiazepine-like compounds in patients with liver cirrhosis. Pharmacol. Res., 35, 557, 1997.
8. Avallone R., Zeneroli M.L., Venturini L., et al. Endogenous benzodiazepine-like compounds and diazepam binding inhibitor in serum of liver cirrhosis patients with and without encephalopathy. Gut, 42, 860, 1998.
9. Gillis J.C., Brogden R.N. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs, 49, 467, 1995.
10. Pugh R.N.H., Murray-Lyon L.M., Dawson J.L., Pietroni M.C., Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg., 60, 646, 1973.
11. Olasmaa M., Rothstein J.D., Guidotti A., et al. Endogenous benzodiazepine in human and animal hepatic encephalopathy. J. Neurochem., 55, 2015, 1990.
12. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248, 1976.
13. Conn H.O., Bircher J. "Hepatic Encephalopathy: Syndromes and Therapies." Medi Ed Press, Bloomington, 1994, pp. 331-349.
14. Olasmaa M., Guidotti A., Costa E., et al. Endogenous benzodiazepines in hepatic encephalopathy. Lancet, 1, 491, 1989.
15. Basile A.S., Gammal S.H., Jones E.A., Skolnick P GABA-A receptor complex in an experimental model of hepatic encephalopathy: Evidence for elevated levels of tin endogenous benzodiazepine receptor complex ligand. J. Neurochem., 53, 1057, 1989.
16. Mullen K.D., Martin J.V., Mendelson W.B., Bassett M.L., Jones E.A. Could tin endogenous benzodiazepine ligand contribute to hepatic encephalopathy? Lancet, 1(8583), 457, 1988.
17. Zeneroli M.L., Venturini L., Corsi L., et al. Benzodiazepine-like compounds in the plasma of patients with fulminant hepatic failure. Scand. J. Gastroenterol., 33, 310, 1998.
18. Avallone R., Corsi L., Zanoli P. Sostanze ad attivitá benzodiazepino-simile in alimenti e in droghe vegetali: Implicazioni fisiologiche e patologiche, Acta Phytoltherap., 3, 42, 1997.
19. Del Piccolo E, Amodio P, Mapelli D., et al. Rifaximin reduces EEG relative beta power inpatients with minimal hepatic encephalopathy: Preliminary findings. In: Jones E.A., Meijer A.J., Chamuleau R.A.F.M. (Eds.). "Encephalopathy and Nitrogen Metabolism in Liver Failure." Kluwer Academic Publishers, Dordrecht, 2003, pp. 361-367.
20. Branch R.A., Morgan M.H., James J., Read A.F. Intravenous administration of diazepam in patients with chronic liver disease. Gut, 17, 975, 1976.
21. Effimiadi C., Deleo C., Schito G.C. Treatment of hepatic encephalopathy with L/105. A new non-absorbable rifamycin. Drug Exptl. Clin. Res., 10, 691, 1984.
22. Als-Nielsen B., Gluud L.L., Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: Systematic review of randomised trials. BMJ, 328, 1046, 2004.
23. Sama C., Morselli-Labate A.M., Pianta R, Lambertini L., Berardi S., Martini G. Clinical effects of rifaximin in patients with hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study. Curr. Ther. Res., 65, 413, 2004.